title: Is another bcr-abl inhibitor needed for chronic myelogenous leukemia?
authors.forename: Edward A
authors.initials: EA
authors.lastname: Sausville
mesh_terms: D001549:Benzamides; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D010879:Piperazines / Q000494:pharmacology; D011725:Pyridines / Q000494:pharmacology; D011743:Pyrimidines / Q000494:pharmacology
chemical_list: D001549:Benzamides; C473352:PD 166326; D010879:Piperazines; D011725:Pyridines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl; C030986:pyrimidine